Guest writer Kylene Henderson's husband had just been diagnosed with PF when they decided to take a family road trip to ...

Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.

The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung ...

Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary fibrosis (IPF), according to new clinical trial data ...

When my husband, Donnie, started exhibiting concerning symptoms in early 2021, we initially attributed it to a lack of exercise during the pandemic or possibly long COVID-19. The initial shortness of ...

What is Jascayd for idiopathic pulmonary fibrosis? Jascayd (nerandomilast) is an approved oral therapy that’s intended to slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF).

In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) ...

Vaccines are a routine part of the pulmonary fibrosis (PF) journey, regardless of where you are along the path. However, recent changes in vaccine guidance from the U.S. Centers for Disease Control ...

Pulmonary fibrosis (PF) is a respiratory disease characterized by fibrosis, or tissue scarring, in the lungs. To function normally, lungs need to be stretchy and elastic like a balloon in order to ...